Szász József Attila, Viorelia Constantin, Mihály István, Biró István, Péter Csongor, Orbán-Kis Károly, Szatmári Szabolcs
Marosvásárhelyi Orvosi és Gyógyszerészeti Egyetem, Marosvásárhely, Románia.
2. Sz. Ideggyógyászati Klinika, Maros Megyei Sürgôsségi Kórház, Marosvásárhely, Románia.
Ideggyogy Sz. 2019 May 30;72(5-6):187-193. doi: 10.18071/isz.72.0187.
There is relatively few data regarding the usage of dopaminagonists for the treatment of Parkinson's disease; furthermore, there are no publications regarding Central- and Eastern-European countries. The aim of the study was to evaluate the use of dopamine agonists as a therapeutic option amongst Parkinson's disease patients admitted to the Neurological Clinics of Tîrgu Mures during the last 15 years.
In our study we investigated the data of all Parkinson's patients treated at our clinics between the 1st of January 2003 and the 31st of December 2017. We analyzed the particularities of dopamine agonists' usage based on the therapeutic recommendations from the final report of these patients. Regarding time since the diagnosis, we divided the patients in two groups: less than or equal to 5 years and more than 5 years.
During the studied period a total of 2379 patients with Parkinson's disease were treated at the Clinics. From the 1237 patients with disease duration under 5 years 665 received dopamine agonists: 120 as monotherapy, 83 together with monoamine oxidase inhibitors and in 234 cases associated with levodopa. The remaining 228 patients were treated with a triple combination of levodopa, dopamine agonists and monoamine oxidase inhibitors. In patients suffering from Parkinson's disease for more than 5 years, in 364 cases out of 653 a dopamine agonist was part of the therapy.
The usage of dopamine agonists was similar to the data presented in other studies. We consider that clinicians treating the disease should, with the necessary prudence, use the available and recommended dopamine agonist with the utmost courage to their maximum therapeutic potential.
关于多巴胺激动剂用于治疗帕金森病的数据相对较少；此外，尚无关于中东欧国家的相关出版物。本研究的目的是评估过去15年中在特尔古穆列什神经科诊所就诊的帕金森病患者中多巴胺激动剂作为一种治疗选择的使用情况。
在我们的研究中，我们调查了2003年1月1日至2017年12月31日期间在我们诊所接受治疗的所有帕金森病患者的数据。我们根据这些患者最终报告中的治疗建议分析了多巴胺激动剂使用的特点。关于诊断后的时间，我们将患者分为两组：小于或等于5年和大于5年。
在研究期间，诊所共治疗了2379例帕金森病患者。在病程小于5年的1237例患者中，665例接受了多巴胺激动剂治疗：120例作为单一疗法，83例与单胺氧化酶抑制剂联合使用，234例与左旋多巴联合使用。其余228例患者接受了左旋多巴、多巴胺激动剂和单胺氧化酶抑制剂的三联组合治疗。在病程超过5年的帕金森病患者中，653例中有364例使用了多巴胺激动剂作为治疗的一部分。
多巴胺激动剂的使用情况与其他研究中的数据相似。我们认为，治疗该疾病的临床医生应谨慎行事，以最大的勇气充分发挥现有推荐的多巴胺激动剂的最大治疗潜力。
